41 results about "Glycogen storage disease" patented technology

The present invention provides deleted adenovirus vectors. The inventive adenovirus vectors carry one or more deletions in the IVa2, 100K, polymerase and / or preterminal protein sequences of the adenovirus genome. The adenoviruses may additionally contain other deletions, mutations or other modifications as well. In particular preferred embodiments, the adenovirus genome is multiply deleted, i.e., carries two or more deletions therein. The deleted adenoviruses of the invention are “propagation-defective” in that the virus cannot replicate and produce new virions in the absence of complementing function(s). Preferred adenovirus vectors of the invention carry a heterologous nucleotide sequence encoding a protein or peptide associated with a metabolic disorder, more preferably a protein or peptide associated with a lysosomal or glycogen storage disease, most preferably, a lysosomal acid α-glucosidase. Further provided are methods for producing the inventive deleted adenovirus vectors. Further provided are methods of administering the deleted adenovirus vectors to a cell in vitro or in vivo.

The present invention relates to a bioactive agent capable of increasing the intracellular concentration and / or activity of Hsp70 for use in the treatment of a lysosomal storage disease which arise from a defect in an enzyme whose activity is not directly associated with the presence of lysosomal BMP as a co-factor; such as glycogen storage diseases, gangliosidoses, neuronal ceroid lipofuscinoses, cerebrotendinous cholesterosis, Wolman's disease, cholesteryl ester storage disease, disorders of glycosaminoglycan metabolism, mucopolysaccharidoses, disorders of glycoprotein metabolism, mucolipidoses, aspartylglucosaminuria, fucosidosis, mannosidoses, and sialidosis type II.

The invention discloses a primer combination, method and kit for constructing a targeted library of multiple inherited metabolic liver diseases based on high-throughput sequencing. The base sequence of the primer combination is shown as SEQ ID No. 1 to SEQ ID No. 2245, and the primer combination covers total 703 exons and cutting regions of 43 genes such as SERPINA1, G6PC, SLC37A4, AGL and the like, and is capable of detecting 41 sub-type gene variation loci of totally 20 inherited metabolic liver diseases comprising alpha-1-antitrypsin deficiency, glycogen storage disease, citrullinemia, aminosuccinuria, hemochromatosis, porphyrinopathy, cystic fibrosis, bile acid synthesis defect, Gaucher disease, hereditary fructose intolerance, cholesterol ester storage disease, Gilbert syndrome, Dubinsyndrome, Rotor syndrome, progressive familial intrahepatic choleatasia and the like. The primer combination disclosed by the invention is simple in operation, high in accuracy and low in time consumption, and the time cost and manual cost used for detecting genes and fragments one by one during Sanger sequencing can be greatly saved.

The present disclosure provides for compositions comprising a chimeric polypeptide comprising a polypeptide effective for treating glycogen storage disease and an internalizing moiety that promotes delivery into cells. In certain embodiments, the polypeptide effective for treating glycogen storage disease is an acid alpha-glucosidase (GAA), a laforin, an amyloglucosidase (AGL), a malin, or an alpha amylase. The present disclosure also provides for methods for decreasing glycogen accumulation in cells or for treating glycogen storage diseases, including Forbes-Cori Disease, Andersen Disease, von Gierke Disease, Pompe Disease, and Lafora Disease, comprising administering the chimeric polypeptide disclosed herein.

The new piperazine derivatives are modulators of TRPML and are useful in treating disorders related to TRPML activities such as lysosome storage diseases, muscular dystrophy, age-related common neurodegenerative diseases, oxidative stress or reactive oxygen species (ROS) related diseases, and ageing.

The invention discloses a new application of recombinant human thymosin alpha collagens, which relates to a recombinant human thymosin alpha collagen. The invention also provides the application of the recombinant human thymosin alpha collagen in preparing anti-fatigue drugs. The recombinant human thymosin alpha collagen (referred to as thymosin alpha collagen) refers to a recombinant human thymosin alpha collagen and a tissue separated and purified thymosin alpha collagen. The effect of the thymosin alpha collagen in various anti-fatigues is implemented through increasing the glycogen storage of the liver and muscles and reducing the level of serum urea nitrogen so as to improve the fatigue resistance.

Substances and methods of use of substances capable of inhibiting serine-palmitoyltransferase (SPT) and / or capable of competing with L-alanine and glycine, including in the reaction catalysed by SPT, including L-serine and D-serine and other compounds, to suppress cytotoxic sphingolipid metabolites, in particular deoxy-sphingolipids. The substances and methods can be used to prevent and treat disease caused by or associated with elevated levels of deoxy-sphingolipids, namely, diabetes (type 1 and type 2 diabetes), particularly diabetic neuropathy, neurodegenerative diseases such as hereditary and sensory neuropathy type I (HSAN1), amyotrophic lateral sclerosis (ALS), Alzheimer disease, other neurological disorders (e.g. depressive disorders, schizophrenia), medication-induced neuriopathies (e.g. induced by treatment with cytostatics like paclitaxel, cis-platin compounds etc.) and other metabolic disorders such as glycogen storage disease type 1a and asthma.

The invention discloses a kit used for screening genetic liver diseases. The kit is high in detection flux, sensitivity, and specificity. The genetic liver diseases comprise progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis, congenital bile acid synthesis defect, idiopathic bile acid malabsorption, Dubin-Johnson syndrome, hereditary hemochromatosis, alpha1 antitrypsin deficiency, glycogen storage disease, autosomal recessive polycystic kidney disease, Budd-Chiari syndrome, and the like. 39 genes, including ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, HSD3B7, AKR1D1, CYP7B1, AMACR, ABCD3, SLC10A2, ABCC2, HFE, TFR2, SERPINA1, G6PC, SLC37A4, AGL, PYGL, SLC40A1, PKHD1, F5, GYS2, VIPAS39, SLC25A13, JAG1, NOTCH2, PHKA2, PHKB, PHKG2, PHKA1, ALAD, HAMP, HFE2, SMPD1, ATP7B, ABCA1, NPC2, and NPC1, are detected in screening of genetic liver diseases. The kit comprises targeting capture probes SEQ NO:1-SEQ NO:722 targeting at all the exons of the 39 genes, and the kitis used for gene detection.

The present invention relates to vectors and compositions for the treatment of glycogen storage disease III.

The invention discloses cyperus esculentus blended soymilk and a producing method thereof. The cyperus esculentus blended soymilk is prepared from soybeans, fresh cyperus esculentus, white granulatedsugar, monoglycerol and diglycerol fatty acid ester and water, and a production technological process of the cyperus esculentus blended soymilk comprises steps of raw material pretreatment, wet superfine grinding, blending, volume metering, homogenizing, filtering, ultrahigh-temperature instantaneous sterilization and sterile filling. The cyperus esculentus blended soymilk is an optimal combination of cyperus esculentus or cyperus esculentus pulp, soybeans or a soybean protein powder and single plant milk in aspects of components, effects, characters and taste. The nutrition is richer, more comprehensive and more balanced; there is no or less sugar and thickening agent; and the soymilk is rich in nutrition, natural, fragrant, sweet and pleasant in taste and more satisfactory, is beneficialto prevention and treatment of metabolic syndromes such as diabetes, a glycogen storage disease, obesity and the like, has no or few side effects such as abdominal distension and diarrhea caused by drinking of the soymilk by people with dyspepsia, hiccup and gastrointestinal dysfunction, and is novel milk replacer plant milk which is suitable for higher nutritional and healthy requirements of wider crowds.

The invention belongs to the field of application of traditional Chinese medicines to adjuvant improvement in the treatment of a kidney function of a chronic kidney disease patient. Renal tubulointerstitial fibrosis is a common pathological process from CKD progress caused by various disease causes to end-stage renal failure, and the anti-renal fibrosis treatment becomes an important link of preventing and delaying the CKD progress. A traditional Chinese medicine composition with a function of adjuvant improvement in the kidney function of the chronic kidney disease patient consists of the following components in parts by weight: 200-600 parts of astragalus membranaceus, 200-600 parts of radix polygonum multiflorum preparata, 100-300 parts of prepared rhubarb, 100-300 parts of ligusticum wallichii, 10-120 parts of leech particles, 200-600 parts of charred fructus crataegi, 200-800 parts of exocarpium benincasae, 100-400 parts of peach kernels, 100-600 parts of centella asiatica and 100-300 parts of herba lycopi. In the formula, the astragalus membranaceus and the radix polygonum multiflorum preparata as monarchs have the efficacies of benefiting Qi and tonifying kidney; the leech particles as ministers have the efficacies of breaking glycogen storage disease, removing blood stasis, promoting blood circulation and prmoting diuresis through channel tunnels; the peach kernels, the ligusticum wallichii, theherba lycopi and the fructus crataegi have the efficacy of promoting blood circulation to remove blood stasis; the prepared rhubarb has the efficacy of dispelling caramelized, damp and turbid blood stasis; the exocarpium benincasae, the herba lycopi and the centella asiatica as adjuvant medicines have the efficacies of dissipating diuresis and dampness. Experiments and clinical trials show that the traditional Chinese medicine composition has the effect of adjuvant treatment on renal insufficiency.

Modified G6PC (glucose-6-phosphatase, catalytic subunit) nucleic acids and glucose-6-phosphatase-alpha (G6Pase-alpha) enzymes with increased phosphohydrolase activity are described. Also described arevectors, such as adeno-associated virus (AAV) vectors, and recombinant AAV expressing modified G6Pase-alpha. The disclosed AAV vectors and rAAV can be used for gene therapy applications in the treatment of glycogen storage disease, particularly glycogen storage disease type la (GSD-Ia), and complications thereof.

The invention discloses a new application of recombinant human thymosin alpha collagens, which relates to a recombinant human thymosin alpha collagen. The invention also provides the application of the recombinant human thymosin alpha collagen in preparing anti-fatigue drugs. The recombinant human thymosin alpha collagen (referred to as thymosin alpha collagen) refers to a recombinant human thymosin alpha collagen and a tissue separated and purified thymosin alpha collagen. The effect of the thymosin alpha collagen in various anti-fatigues is implemented through increasing the glycogen storage of the liver and muscles and reducing the level of serum urea nitrogen so as to improve the fatigue resistance.

The present invention relates to a mini-GDE for the treatment of glycogen storage disease III.

The present invention provides deleted adenovirus vectors. The inventive adenovirus vectors carry one or more deletions in the IVa2, 100 K, polymerase and / or preterminal protein sequences of the adenovirus genome. The adenoviruses may additionally contain other deletions, mutations or other modifications as well. In particular preferred embodiments, the adenovirus genome is multiply deleted, i.e., carries two or more deletions therein. The deleted adenoviruses of the invention are “propagation-defective” in that the virus cannot replicate and produce new virions in the absence of complementing function(s). Preferred adenovirus vectors of the invention carry a heterologous nucleotide sequence encoding a protein or peptide associated with a metabolic disorder, more preferably a protein or peptide associated with a lysosomal or glycogen storage disease, most preferably, a lysosomal acid α-glucosidase. Further provided are methods for producing the inventive deleted adenovirus vectors. Further provided are methods of administering the deleted adenovirus vectors to a cell in vitro or in vivo.

This invention provides a variety of novel adeno-associated virus (AAV) vectors for gene therapy applications in the treatment of glycogen storage disease type la (GSD-Ia). Disclosed herein are a number of recombinant nucleic acid molecules, vectors and recombinant AAV that incorporate a modified G6PC promoter / enhancer sequence. Utilization of the modified G6PC promoter / enhancer sequence results in enhanced AAV yield and quality when expressed from various host cell platforms. Also provided herein are compositions comprising the novel AAV of the invention and methods of treating GSD-Ia using the same.

The invention provides a sustained-release glucose preparation for treating glycogen storage diseases and a preparation method thereof, belonging to the field of medicinal preparations. The sustained-release glucose preparation is composed of two parts, i.e., a glucose pill core and a film coating and prepared from glucose monohydrate, microcrystalline cellulose, ethyl cellulose, hydroxypropyl cellulose, triethyl citrate, ethanol and purified water by using a modern preparation technology. Results of release-rate determination experiments prove that the sustained-release glucose preparation provided by the invention has good sustained-release performance and can be gradually and slowly released within 6 h; the release rates of sustained-release glucose preparations prepared according to three different prescriptions are 40 to 70% within 6 h; so the sustained-release glucose preparation can replace raw core starch and be used for treatment of glycogen storage diseases.

This disclosure provides isolated nucleic acid molecules comprising nucleic acid sequences encoding microbial polypeptides that are codon optimized for expression in mammalian cells, vectors comprising an immunotolerant dual promoter system, and methods using these polynucleotides and polypeptides to treat glycogen storage diseases and other inherited diseases.

The present invention relates to vectors and compositions for the treatment of glycogen storage disease III.

The invention provides a sustained-release glucose preparation for treating glycogen storage diseases and a preparation method thereof, belonging to the field of medicinal preparations. The sustained-release glucose preparation is composed of two parts, i.e., a glucose pill core and a film coating and prepared from glucose monohydrate, microcrystalline cellulose, ethyl cellulose, hydroxypropyl cellulose, triethyl citrate, ethanol and purified water by using a modern preparation technology. Results of release-rate determination experiments prove that the sustained-release glucose preparation provided by the invention has good sustained-release performance and can be gradually and slowly released within 6 h; the release rates of sustained-release glucose preparations prepared according to three different prescriptions are 40 to 70% within 6 h; so the sustained-release glucose preparation can replace raw core starch and be used for treatment of glycogen storage diseases.

Vectors including viral vectors comprising a genome comprising a heterologous nucleic acid encoding a lysosomal targeting sequence, fused to a lysosomal storage enzyme, enabling the lysosomal enzyme to be targeted to the lysosomes. Particular embodiments relate to a recombinant viral vector, e.g., rAAV vector encoding a lysosomal enzyme, having a lysosomal targeting IGF2(V43) sequence that binds human cation-independent mannose-6-phosphate receptor (CI-MPR) or to the IGF2 receptor, permitting proper subcellular localization of the lysosomal enzyme polypeptide to lysosomes. Also encompassed are therapeutic fusion proteins encoded by the viral vector, non-viral vectors, cells, and methods to treat a glycogen storage disease, e.g., those listed in Table 4A or Table 5A with the viral vector. t,?